Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

58.6K
Precise measurement of neurological and neuropsychological impairment and disability in multiple sclerosis is challenging. We report methodologic details on a new test, the Multiple Sclerosis Performance Test (MSPT). This new approach to the objective of quantification of MS related disability provides a computer-based platform for precise, valid measurement of MS...
58.6K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

12.0K
Multiple sclerosis is an inflammatory demyelinating disease with no cure. Analysis of brain tissue provides important clues to understanding the pathogenesis of the disease. Here we discuss the methodology and downstream analysis of MS brain tissue collected through a unique rapid autopsy program in operation at the Cleveland...
12.0K
Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

8.7K
Cognitive deficits are common in about one third of patients with amyotrophic lateral sclerosis, a neurological condition leading to progressive impairments in speech and movement abilities. To conduct cognitive tests in patients unable to speak or write a reliable and easy to administer eye-tracking paradigm was...
8.7K
A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

18.1K
The goal of this pilot study is to describe a protocol for the remotely-supervised delivery of transcranial direct current stimulation (tDCS) so that the procedure maintains standards of in-clinic practice, including safety, reproducibility, and tolerability. The feasibility of this protocol was tested in participants with multiple sclerosis (MS).
18.1K
Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage06:46

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage

12.7K
This paper describes a protocol for cognitive assessments for genetic models of the Alzheimer's disease using the IntelliCage system, which is a high throughput automated behavioral monitoring system with operant...
12.7K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

11.5K
An optimized testing protocol is presented in this paper for the Rotarod performance test, used for measuring progressive neurological disability in TMEV-infected mice.
11.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Breaking the Vicious Cycle? A Systematic Review of Interventions Targeting Both Falls and Fear of Falling in Older Adults.

Geriatrics (Basel, Switzerland)·2026
Same author

Word finding difficulties in multiple sclerosis and its relation to cognitive impairment, fatigue and depression.

Multiple sclerosis and related disorders·2026
Same author

Manual Dexterity Shows Greater Discretionary Value than Sensor-Based Gait and Balance Measures in Identifying Early Functional Impairment in Multiple Sclerosis.

Sensors (Basel, Switzerland)·2026
Same author

Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategies.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

The association between objective measures of sleep and physical activity in individuals with multiple sclerosis.

Multiple sclerosis and related disorders·2025
Same author

Disease-Modifying Treatment Options in Very Early Onset Multiple Sclerosis-What Choices Are There for Onset Under 5 Years of Age? A Systematic Review.

Journal of clinical medicine·2025

Related Experiment Video

Updated: Jan 20, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.6K

Cognitive function in multiple sclerosis: A long-term look on the bright side.

Yermi Harel1,2,3, Alon Kalron4,5, Shay Menascu1

  • 1Multiple Sclerosis Center, Sheba Medical Center, Tel Hashomer, Israel.

Plos One
|August 30, 2019
PubMed
Summary

Most multiple sclerosis (MS) patients on disease-modifying drugs (DMD) maintain cognitive function despite long disease duration. A significant portion exhibit cognitive resilience, showing high performance and mild disability.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.0K
Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

8.7K

Related Experiment Videos

Last Updated: Jan 20, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.6K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.0K
Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

8.7K

Area of Science:

  • Neuroscience
  • Clinical Neurology
  • Immunology

Background:

  • Multiple sclerosis (MS) is a chronic neurological disease that can lead to progressive cognitive impairment over time.
  • Cognitive decline in MS can significantly impact a patient's quality of life and functional independence.
  • Understanding factors influencing cognitive outcomes in long-standing MS is crucial for effective management.

Purpose of the Study:

  • To assess cognitive performance in patients with multiple sclerosis (MS) and long disease duration who are treated with disease-modifying drugs (DMD).
  • To examine the relationship between cognitive performance, neurological disability (assessed by EDSS), and prevalence of cognitive resilience in this patient cohort.
  • To determine if DMD treatment duration influences cognitive outcomes in long-term MS patients.

Main Methods:

  • A cohort of 1010 DMD-treated MS patients with at least 10 years disease duration was evaluated.
  • Cognitive performance was categorized as high, moderate, or low.
  • Neurological disability was assessed using the Expanded Disability Status Scale (EDSS) (mild, moderate, severe).

Main Results:

  • After a mean of 19.6 years, 33.7% of patients demonstrated high cognitive performance (cognitively resilient), 42.7% moderate, and 23.7% low cognitive performance.
  • Patients with high cognitive performance predominantly had mild disability (64.4%), while those with low cognitive performance often had severe disability (50.6%).
  • Disease-modifying drug (DMD) treatment duration did not significantly account for the observed differences in cognitive performance relative to disability levels.

Conclusions:

  • The majority of MS patients receiving DMD treatment maintain cognitive function that does not impair their quality of life, even after extended disease duration.
  • Cognitive resilience is present in a substantial proportion of long-term MS patients.
  • Neurological disability status is strongly associated with cognitive performance levels in MS patients on long-term DMD therapy.